Evidence map›Paper›PMID 28433654›Full record

ArticleStem cell research2017

High molecular weight FGF2 isoforms demonstrate canonical receptor-mediated activity and support human embryonic stem cell self-renewal.

Denis Kole, Alexandra Grella, David Dolivo, Lucia Shumaker, William Hermans, Tanja Dominko

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Denis KoleWorcester Polytechnic Institute, Department of Biology and Biotechnology, 100 Institute Road, Worcester, MA 01609, United States.
Alexandra GrellaWorcester Polytechnic Institute, Department of Biology and Biotechnology, 100 Institute Road, Worcester, MA 01609, United States.
David DolivoWorcester Polytechnic Institute, Department of Biology and Biotechnology, 100 Institute Road, Worcester, MA 01609, United States.
Lucia ShumakerWorcester Polytechnic Institute, Department of Biology and Biotechnology, 100 Institute Road, Worcester, MA 01609, United States.
William HermansBlue Sky Bioservices Inc., 60 Prescott Street, Worcester, MA 01605, United States.
Tanja DominkoWorcester Polytechnic Institute, Department of Biology and Biotechnology, 100 Institute Road, Worcester, MA 01609, United States; University of Nova Gorica, Center for Biomedical Sciences and Engineering, Glavni trg 8, Vipava, Slovenia. Electronic address: tdominko@wpi.edu.
Worcester Polytechnic Institute · USBluebird Bio (United States) · US

Funding

De-Differentiating Adult Human Fibroblasts into Stem-Like Cells Using ConditionsR01GM085456 · NIGMS · WORCESTER POLYTECHNIC INSTITUTE · PI DOMINKO, TANJA · 2008 to 2010
$981k
NIGMS NIH HHS R01 GM085456
6 · The paper itself

Abstract

Basic fibroblast growth factor (FGF2) is a highly pleiotropic member of a large family of growth factors with a broad range of activities, including mitogenesis and angiogenesis (Ornitz et al., 1996; Zhang et al., 2006), and it is known to be essential for maintenance of balance between survival, proliferation, and self-renewal in human pluripotent stem cells (Eiselleova et al., 2009; Zoumaro-Djayoon et al., 2011). A single FGF2 transcript can be translated into five FGF2 protein isoforms, an 18kDa low molecular weight (LMW) isoform and four larger high molecular weight (HMW) isoforms (Arese et al., 1999; Arnaud et al., 1999). As they are not generally secreted, high molecular weight (HMW) FGF2 isoforms have predominantly been investigated intracellularly; only a very limited number of studies have investigated their activity as extracellular factors. Here we report over-expression, isolation, and biological activity of all recombinant human FGF2 isoforms. We show that HMW FGF2 isoforms can support self-renewal of human embryonic stem cells (hESCs) in vitro. Exogenous supplementation with HMW FGF2 isoforms also activates the canonical FGFR/MAPK pathway and induces mitogenic activity in a manner similar to that of the 18kDa FGF2 isoform. Though all HMW isoforms, when supplemented exogenously, are able to recapitulate LMW FGF2 activity to some degree, it appears that certain isoforms tend to do so more poorly, demonstrating a lesser functional response by several measures. A better understanding of isoform-specific FGF2 effects will lead to a better understanding of developmental and pathological FGF2 signaling.

Indexed as

Cell Self RenewalAnimalsBase SequenceCell LineCell ProliferationCell ShapeDermisFibroblast Growth Factor 2FibroblastsHuman Embryonic Stem CellsHumansMiceMitogensMolecular WeightProtein IsoformsReceptors, Fibroblast Growth FactorFibroblast Growth Factor 2MitogensProtein IsoformsReceptors, Fibroblast Growth Factor

Identifiers

PMID28433654
PMCPMC5504699
OpenAlexW2607232603

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.